1. Perspectives on Key MS Data From the Annual European MS Meeting

2. Integrating MRI Cortical Lesions in the Diagnosis of MS

3. Integrating MRI Cortical Lesions in the Diagnosis of MS (cont)

4. CARE MS I & II: MRI-Detected Lesions and NEDA

5. CARE-MS I and II: Rate of BVL

6. Spinal Cord Volume

7. Brain Atrophy as a Surrogate Marker for MS Progression

8. Perspectives on Key MS Data From the Annual European MS Meeting

9. Long-Term Effect of Therapy Effect of Year of MS Diagnosis on Reaching EDSS of 6

10. CARE-MS II: 5-Year Outcomes in Patients With HAD at Baseline

11. CARE-MS I and II: Autoimmunity With Alemtuzumab

12. CARE-MS I and II: Autoimmunity With Alemtuzumab (cont)

13. Use of Modified MSFC to Assess Efficacy of Daclizumab HYP and IFN-β1a IM on 24-Week Sustained Disability Progression

14. Use of Modified MSFC to Assess Efficacy of Daclizumab HYP and IFN-β1a IM on 24-Week Sustained Disability Progression (cont)

15. ENDORSE: Study Design

16. ENDORSE: Results

17. Perspectives on Key MS Data From the Annual European MS Meeting

18. NEDA: Definitions

19. Prognosis: ADVANCE and ATTAIN*

20. Prognosis: FREEDOMS and FREEDOMS II

21. Prognosis: FREEDOMS and FREEDOMS II (cont)

22. Achieving NEDA: DECIDE

23. Achieving NEDA: CLARITY and ONWARD

24. NEDA as Long-Term Therapeutic Goal: CARE-MS

25. NEDA: Practice Implications

26. NEDA: Practice Implications (cont)

27. NEDA: Practice Implications (cont)

28. Perspectives on Key MS Data From the Annual European MS Meeting

29. EXPAND: Siponimod in SPMS

30. RADIANCE Extension -- Ozanimod: Design

31. RADIANCE Extension -- Ozanimod: Results

32. ORATORIO: Subgroup Analysis

33. Autologous HSCT

34. ASCEND: Subgroup Analysis -- Design

35. ASCEND: Subgroup Analysis – Results

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)